Bacteriófagos como posible terapia antibacteriana frente a pseudomona aeruginosa en pacientes con quemaduras

Maria Fernanda Paredes Condo; Álvaro Sebastián  Ron Mora

doi:10.59169/pentaciencias.v5i5.760

Authors

Maria Fernanda Paredes Condo Universidad Técnica de Ambato
Álvaro Sebastián Ron Mora Universidad Técnica de Ambato https://orcid.org/0000-0003-1157-1661

DOI:

https://doi.org/10.59169/pentaciencias.v5i5.760

Keywords:

Bacteriophages; Antimicrobial; Pseudomona aeruginosa; Multidrug-resistant.

Abstract

Pseudomonas aeruginosa is one of the most relevant infectious bacterial pathogens, resulting in high morbidity and mortality rates among hospitalized patients with burns due to its easy development of resistance to multiple classes of antibiotics. This constitutes a significant health problem due to the increased virulence factors, expression of resistance-related enzymes, and the development of biofilms. Due to the emergence of resistance, alternative phage therapy has been considered. To describe therapeutic failure with antibiotics and specify the bacteriophages that have been studied as a potential antibacterial treatment against Pseudomonas aeruginosa. This literature review was conducted using a documentary approach with a descriptive and retrospective analysis. Scientific articles in English and Spanish published from 2017 onwards until 2023 were utilized. Specific phages, Pa1 and Pa2, belonging to Caudovirales and Siphoviridae family, were identified as highly stable phages with significant potential, confirming that lytic phages can be used as an effective agent against the bacterial pathogen Pseudomonas aeruginosa. However, phage therapy in humans is still under development and has not been established as a widespread clinical practice.

Downloads

Download data is not yet available.

References

Jeschke, M. G., van Baar, M. E., Choudhry, M. A., Chung, K. K., Gibran, N. S., & Logsetty, S. (2020). Burn injury. Nature Reviews. Disease Primers, 6(1), 11. https://doi.org/10.1038/s41572-020-0145-5

Dvorak, J. E., Ladhani, H. A., & Claridge, J. A. (2021). Review of sepsis in burn patients in 2020. Surgical Infections, 22(1), 37–43. https://doi.org/10.1089/sur.2020.367

Ozlu, O., & Basaran, A. (2022). Infections in patients with major burns: A retrospective study of a burn intensive care unit. Journal of Burn Care & Research: Official Publication of the American Burn Association, 43(4), 926–930. https://doi.org/10.1093/jbcr/irab222

Albayrak, Y. (2020). Factors affecting the mortality at patients with burns: Single centre results. Ulusal travma ve acil cerrahi dergisi [Turkish journal of trauma & emergency surgery], 26(5). https://doi.org/10.14744/tjtes.2020.37862

Paz-Zarza, V. M., Mangwani-Mordani, S., Martínez-Maldonado, A., Álvarez-Hernández, D., Solano-Gálvez, S. G., & Vázquez-López, R. (2019). Pseudomonas aeruginosa: patogenicidad y resistencia antimicrobiana en la infección urinaria. Revista Chilena de Infectologia: Organo Oficial de La Sociedad Chilena de Infectologia, 36(2), 180–189. https://doi.org/10.4067/s0716-10182019000200180

Pinzón-Junca, A. (2019). Pseudomonas. Acta medica colombiana: AMC: organo de la Asociacion Columbiana de Medicina Interna, 44(1), 52–52. http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-24482019000100052&lng=en&nrm=iso

Barbecho Coraisaca, D. V. (2021). Susceptibilidad antimicrobiana en Pseudomona spp., en el Hospital General Docente Cuenca-Ecuador. Revista Vive, 4(12), 484–499. https://doi.org/10.33996/revistavive.v4i12.108

Hernández, A., Yagüe, G., García Vázquez, E., Simón, M., Moreno Parrado, L., Canteras, M., & Gómez, J. (2018). Nosocomial infections caused by multiresistant Pseudomonas aeruginosa (carbapenems included): predictive and prognostic factors. A prospective study (2016-2017)). Revista espanola de quimioterapia: publicacion oficial de la Sociedad Espanola de Quimioterapia, 31(2), 123–130.

La OMS publica la lista de las bacterias para las que se necesitan urgentemente nuevos antibióticos. (s/f). Who.int. Recuperado el 7 de julio de 2023, de https://www.who.int/es/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed

Cejas C. (2021). Fagoterapia: Tratamiento alternativo para el Control de las Infecciones Bacterianas en Pacientes Quemados. (s. f.). Revista Argentina de Quemaduras. https://raq.fundacionbenaim.org.ar/fagoterapia-tratamiento-alternativo-para-el-control-de-las-infecciones-bacterianas-en-pacientes-quemados/

Díaz Santos, E., Mora Jiménez, C., Del Río-Carbajo, L., & Vidal-Cortés, P. (2022). Treatment of severe multi-drug resistant Pseudomonas aeruginosa infections. Medicina Intensiva (English Edition), 46(9), 508–520. https://doi.org/10.1016/j.medine.2022.06.014

Pachay Solórzano, J. W., & Pachay Parrales, V. E. (2021). Pseudomonas aeruginosa y su evolución de resistencia a los antibióticos en un hospital de segundo nivel en Portoviejo, Ecuador. QhaliKay. Revista de Ciencias de la Salud ISSN: 2588-0608, 5(2), 50. https://doi.org/10.33936/qkrcs.v5i2.3002

Salinas Martínez, C., Luna, A. H., Oropeza, R., Olvera Guzmán, C., Morales, M. P., Franco Granillo, J., De Medicina Crítica, D., Shapiro, M., Médico, C.-T., De Farmacia, J., & Médico, C. (s/f). Colistin en el tratamiento de infección por Pseudomonas aeruginosa multidrogorresistente. Medigraphic.com. Recuperado el 7 de julio de 2023, de https://www.medigraphic.com/pdfs/medcri/ti-2010/ti104d.pdf

Angles-Yanqui, E., Chumbes-Pérez, J., & Huaringa-Marcelo, J. (2020). Colistina en el tratamiento de infecciones por pseudomonas aeruginosa y acinetobacter baumannii extensivamente resistentes (XDR) en un hospital de tercer nivel. Infectio: revista de la Asociacion Colombiana de Infectologia, 24(4), 201. https://pesquisa.bvsalud.org/portal/resource/pt/biblio-1114869

Zarate, M., Barrantes, D., Cuicapuza, D., Velasquez, J., Fernández, N., Salvatierra, G., & Tamariz, J. (2021). Frecuencia de resistencia a la colistina en Pseudomonas aeruginosa: primer reporte en el Perú. Revista peruana de medicina experimental y salud pública, 38(2), 308–312. https://doi.org/10.17843/rpmesp.2021.382.6977

Khalili, Y., Memar, M. Y., Farajnia, S., Adibkia, K., Kafil, H. S., & Ghotaslou, R. (2021). Molecular epidemiology and carbapenem resistance of Pseudomonas aeruginosa isolated from patients with burns. Journal of Wound Care, 30(2), 135–141. https://doi.org/10.12968/jowc.2021.30.2.135

Hatfull, G. F., & Hendrix, R. W. (2011). Bacteriophages and their genomes. Current Opinion in Virology, 1(4), 298–303. https://doi.org/10.1016/j.coviro.2011.06.009

Harada, L. K., Silva, E. C., Campos, W. F., Del Fiol, F. S., Vila, M., Dąbrowska, K., Krylov, V. N., & Balcão, V. M. (2018). Biotechnological applications of bacteriophages: State of the art. Microbiological Research, 212–213, 38–58. https://doi.org/10.1016/j.micres.2018.04.007

Domínguez Navarrete, N. (2020). Bacteriófagos. Revista de la Facultad de Medicina Humana, 20(1), 164–165. https://doi.org/10.25176/rfmh.v20i1.2554

Straka, M., Dubinová, M., & Liptáková, A. (2022). Phascinating phages. Microorganisms, 10(7). https://doi.org/10.3390/microorganisms10071365

Jamal, M., Bukhari, S. M. A. U. S., Andleeb, S., Ali, M., Raza, S., Nawaz, M. A., Hussain, T., Rahman, S. U., & Shah, S. S. A. (2018). Bacteriophages: an overview of the control strategies against multiple bacterial infections in different fields. Journal of Basic Microbiology, 59(2), 123–133. https://doi.org/10.1002/jobm.201800412

Marei, E. M. (2020). Isolation and Characterization of Pseudomonas aeruginosa and its Virulent Bacteriophages. Pakistan Journal of Biological Sciences: PJBS, 23(4), 491–500. https://doi.org/10.3923/pjbs.2020.491.500

Chegini, Z., Khoshbayan, A., Taati Moghadam, M., Farahani, I., Jazireian, P., & Shariati, A. (2020). Bacteriophage therapy against Pseudomonas aeruginosa biofilms: a review. Annals of Clinical Microbiology and Antimicrobials, 19(1), 45. https://doi.org/10.1186/s12941-020-00389-5

Wang, J., Zhou, M., Huang, G., Guo, Z., Sauser, J., Metsini, A., Pittet, D., & Zingg, W. (2020). Antimicrobial resistance in southern China: results of prospective surveillance in Dongguan city, 2017. The Journal of Hospital Infection, 105(2), 188–196. https://doi.org/10.1016/j.jhin.2020.03.029

Zhang, Y., Zhong, Z.-F., Chen, S.-X., Zhou, D.-R., Li, Z.-K., Meng, Y., Zhou, J.-F., & Hou, T.-Y. (2019). Prevalence of healthcare-associated infections and antimicrobial use in China: Results from the 2018 point prevalence survey in 189 hospitals in Guangdong Province. International Journal of Infectious Diseases: IJID: Official Publication of the International Society for Infectious Diseases, 89, 179–184. https://doi.org/10.1016/j.ijid.2019.09.021

Salinas-Salcedo, I. A., Saldaña-Jiménez, J. A., Guevara-Canales, J. M., & Gonzales-Escalante, E. (2020). Utilidad de la citometría de flujo para la detección de Pseudomonas aeruginosa productoras de metalobetalactamasas. Revista peruana de medicina experimental y salud pública, 37(4), 700–704. https://doi.org/10.17843/rpmesp.2020.374.4825

Gaete, M. A., Valenzuela, M., Bachero, A. V., Vega, C. R. C., Marín, N., Labarca, J., & Cañete, P. (2020). Carbapenemasas en Pseudomonas aeruginosa con susceptibilidad disminuida a los carbapenémicos después de una década, desde VIM a KPC. Revista Chilena De Infectologia, 37(4), 389–394. https://doi.org/10.4067/s0716-10182020000400389

Tooke, C. L., Hinchliffe, P., Bragginton, E. C., Colenso, C. K., Hirvonen, V. H. A., Takebayashi, Y., & Spencer, J. (2019). Β-lactamases and β-lactamase inhibitors in the 21st century. Journal of Molecular Biology, 431(18), 3472–3500. https://doi.org/10.1016/j.jmb.2019.04.002

Lichtenberg, M., Jakobsen, T. H., Kühl, M., Kolpen, M., Jensen, P. Ø., & Bjarnsholt, T. (2022). The structure-function relationship of Pseudomonas aeruginosa in infections and its influence on the microenvironment. FEMS Microbiology Reviews, 46(5). https://doi.org/10.1093/femsre/fuac018